Literature DB >> 19373047

Magic bullets and surrogate biomarkers circa 2009.

Matthew J Delano, Lyle L Moldawer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19373047      PMCID： PMC4010118          DOI： 10.1097/CCM.0b013e3181a09440

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  21 in total

Review 1.  Novel strategies for the treatment of sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Peter A Ward
Journal:  Nat Med       Date:  2003-05       Impact factor: 53.440

Review 2.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

3.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

4.  Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

Authors:  Marcin F Osuchowski; Judith Connett; Kathleen Welch; Jill Granger; Daniel G Remick
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

5.  Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.

Authors:  Peter Q Eichacker; Chantal Parent; Andre Kalil; Claire Esposito; Xizhong Cui; Steven M Banks; Eric P Gerstenberger; Yvonne Fitz; Robert L Danner; Charles Natanson
Journal:  Am J Respir Crit Care Med       Date:  2002-11-01       Impact factor: 21.405

6.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

7.  Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.

Authors:  K Reinhart; T Menges; B Gardlund; J Harm Zwaveling; M Smithes; J L Vincent; J M Tellado; A Salgado-Remigio; R Zimlichman; S Withington; K Tschaikowsky; R Brase; P Damas; H Kupper; J Kempeni; J Eiselstein; M Kaul
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

8.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

9.  Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days.

Authors:  Daniel G Remick; Gerald R Bolgos; Javed Siddiqui; Jungsoon Shin; Jean A Nemzek
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

Review 10.  Clinical review: corticotherapy in sepsis.

Authors:  Helene Prigent; Virginie Maxime; Djillali Annane
Journal:  Crit Care       Date:  2003-09-29       Impact factor: 9.097
View more
  10 in total

Review 1.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality?

Authors:  Matthew J Delano; Peter A Ward
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 2.  Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Authors:  Joseph M Cicchese; Stephanie Evans; Caitlin Hult; Louis R Joslyn; Timothy Wessler; Jess A Millar; Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; Denise E Kirschner
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

Review 3.  The immune system's role in sepsis progression, resolution, and long-term outcome.

Authors:  Matthew J Delano; Peter A Ward
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 4.  Is there value in plasma cytokine measurements in patients with severe trauma and sepsis?

Authors:  Lori F Gentile; Alex G Cuenca; Erin L Vanzant; Philip A Efron; Bruce McKinley; Frederick Moore; Lyle L Moldawer
Journal:  Methods       Date:  2013-05-11       Impact factor: 3.608

5.  IL-10 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development.

Authors:  Isatou Bah; Ajinkya Kumbhare; Lam Nguyen; Charles E McCall; Mohamed El Gazzar
Journal:  Cell Immunol       Date:  2018-07-11       Impact factor: 4.868

6.  Experimentally approaching the ICU: monitoring outcome-based responses in the two-hit mouse model of posttraumatic sepsis.

Authors:  Susanne Drechsler; Katrin M Weixelbaumer; Heinz Redl; Martijn van Griensven; Soheyl Bahrami; Marcin F Osuchowski
Journal:  J Biomed Biotechnol       Date:  2011-01-18

Review 7.  Mitochondrial Dysfunction and Immune Cell Metabolism in Sepsis.

Authors:  Dae Won Park; Jaroslaw W Zmijewski
Journal:  Infect Chemother       Date:  2017-03

Review 8.  The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3.

Authors:  Renyu Ding; Yulan Meng; Xiaochun Ma
Journal:  Biomed Res Int       Date:  2018-06-07       Impact factor: 3.411

Review 9.  Diabetes and Sepsis: Risk, Recurrence, and Ruination.

Authors:  Lynn M Frydrych; Fatemeh Fattahi; Katherine He; Peter A Ward; Matthew J Delano
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-30       Impact factor: 5.555

10.  Early label-free analysis of mitochondrial redox states by Raman spectroscopy predicts septic outcomes.

Authors:  Meiyan Wu; Kairui Pu; Tao Jiang; Qian Zhai; Zhi Ma; Hongli Ma; Fuxing Xu; Zhanqin Zhang; Qiang Wang
Journal:  J Adv Res       Date:  2020-07-02       Impact factor: 10.479
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.